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SAFETY, TOLERABILITY AND DRUG INTERACTIONS OF ADJUVANT 
IMATINIB MESYLATE (GLEEVEC®) WITHIN THE FIRST I00 DAYS 
FOLLOWING STEM CELL TRANSPLANTATION (SCT) IN PATIENTS 
WITH PH+ CML AND PH+ ALL AT HIGH RISK FOR RECURRENCE 
Sheth, S.R.; Hick6 K.; Ippoliti, C.; Giralt, S., ChawpliJz, R.E.; A~zder- 
lin], P. Unive1"sitv of Terns 3/1. D.Amlerson &racer Ce'nte'~, Departme17t 
qfl Blood aTzd MaTv'ow T'lrnzspla~tation, Hoz~'ton, TX. 
A study (chart review) was conducted to evaluate the tolerability 
and toxicity of ilnatinib when used within the first 100 days fol- 
lowing SeT  in patients without evidence of active disease but at 
high risk for recurrence. Data collected included assessment of 
patient tolerance to imatinib dose escalation, maximum tolerated 
dosage, influence of imatinib administration on tacrolimus ermn 
concentrations, and hematologic and non-hematologic toxicities 
related to imatinib use in SCT recipients. SCT patients (n-15; 
M/F 12/3) ranging in age from 16-69 years (mean = 42 years) 
received imatinib as adjuvant herapy following SCT during the 
period 5/2001-6/2002. Disease states included Ph+ CML (n=8), 
Ph+ ALL (n=6) and Ph+ AML (n=l). Stern cell source included 
peripheral blood in 9/15 patients (60%), and bone marrow (n=6). 
9/15 patients (60%) received their SCT from an HLA matched 
sibling, 3/15 (20%) from a matched unrelated donor,  2/15 
(I 2.4%) from a 1-antigen mismatched related donor, and I patient 
received autologous SCT. Median day of imatinib initiation was 
day +34 after SCT (range 16-37). Initial imatinib doses ranged 
from 100 to 400 mg/day. The average daily dose was 100 rag/day. 
Doses exceeding 200 mg/day were associated with myelosuppres- 
sion, which required both imatinib dose reduction and initiation 
of transfusion and growth factor support measures to achieve graft 
recovery. At all doses, imatinib was associated with reversible 
hematological toxicity, with Grade 3 and 4 neutropenia observed 
in 40% and 27% of patients respectively. Significant hrombocy- 
topenia was also noted; with Grade 3 and 4 toxicity observed in 
27% and 20% of all patients evaluated. Non-hematologic toxici- 
ties were uncommon; with periorbital edema/weight gain and 
transient elevation in total bi l irubin (i.0 mg/dl to 2.3 mg/dl) 
noted in 1 patient each (6.7%). Administration of imatinib was 
found to predictably increase tacrolimus erum levels by 25-33 % 
within 72 hours of medication initiation. Empiric tacrolimus dose 
reduction of 25% prevented further serum concentration fluctna- 
tions. These preliminary observations suggest hat imatinib can be 
safely administered within the first 100 days s/p SCT, although 
the tolerated oses are usually lower than in non-SCT patients. 
141 
AN INTENT TO TREAT ANALYSIS OF CHEMOTHERAPY VERSUS ALLO- 
GENEIC BONE MARROW TRANSPLANT IN FIRST COMPLETE REMIS- 
SION (CRI) FOR ADULT PATIENTS BELOW THE AGE 55 YEARS WITH 
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)" RESULTS FROM PRINCESS 
MARGARET HOSPITAL 
Gapta, U/; Yi, Q.2; 3/lk~de11, M.D/;  LiptoJz, J .H/ ;  Branclweim j.l: 
Daly, A.1; ~,fTells. ' R.AJ; Schtzh, A. z; Kiss, T.1; MessneJ; H. 1 I. Leztkemia 
aJzd tr_am'p/a,~t Program, Dept. of Medical OJTco/ogy mzd Hematology, 
Prilzcess Margaret Hospital, Toronto, ON, Cm~ada; 2. Dept. of Biosta- 
tistiL:r, P*qlzcess Margm'et Hospital, Tm'o1~to, ON, &mada. 
The role of alloBMT for adults with ALL in CRI is disputed. 
At our center, treatment policy is to offer these patients (pts) 
alloBMT in CR1 up to the age of 55 years (yrs) ifa related donor 
(either fully matched or one antigen mismatched) is available. In 
addition, unrelated donor transplants (UD) are offered to 
Philadelphia positive (Ph+) ALL pts in CR1. Pts without a donor 
are treated with intensification and maintenance chemotherapy 
(CT) for 2 yrs. This retrospective analysis was done to evaluate 
the efficacy of this treatment policy. From 09/92 to 10/01, 97 
new pts between the ages 16 to 55 yrs with the diagnosis of ALL 
(mature B ALL and acute biphenotypic leukemia pts excluded) 
were seen at PMH. Five pts (3 treated with palliative CT  due to 
co-morbid conditions, 1 incomplete follow-up & 1 Jehovah's wit- 
ness) were excluded from this analysis. Of the evaluable 92 pts, 
87 (94%) acheived CR1 and included individuals with standard 
risk, n=30; high-risk, n=46; risk not assessable, n=l 1. High-risk 
was defined as presence of one of the following features: WBC 
>30xl0°/L for B-lineage and >100xl09/L for T lineage, time to 
CR>5 weeks, cytogenetics abnormalities as Ph+ or t (4; 11). 49 
pts had a donor (36 HLA identical, 4 one antigen mismatched, i 
haplo-identical nd 8 UD) and were designated as alloBMT arm. 
In the alloBMT arm, 43 pts received transplants (35 in CR1, 7 in 
CR2, 1 aplastic phase of salvage CT). Of the 43 pts on the CT  
arm, 6 pts received a rescue transplant in CR2 from UD. Median 
age in the CT  and al loBMT arm was 25 and 34 yrs (p0.21) 
respectively. Median time to transplant was 189 and 375 days for 
pts transplanted in CR1 and CR2 respectively. In an intent to 
treat analysis, a non-significant trend towards better 3 yr. disease- 
free survival (DFS) was seen in the alloBMT ann (53% vs. 40%, 
p 0.29). When these results were analyzed according to risk strat- 
ification, a benefit of alh)BMT was seen only in high-risk group 
respect o DFS in favor of alloBMT arm (54% vs. 25%, p0.05). 
Given the limitation of a small sample size, it seems reasonable to 
recommend al loBMT for high-risk ALL pts in CR1. Further 
data are needed to decide the utility of this approach in standard 
risk pts. 
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SUCCESSFUL ALLOGENEIC HSCT FOR CONSOLIDATION IN YOUNG 
CHILDREN WITH HIGH-RISK I IQ23+ ALL IN CRI 
Quino~zes, R.R/; Hzmger, S.fU; Go~'e, L/; Gm'ce& R.L/; Garrington, 
T.PJ; Foremalz, N.K/; Makolm, ft.:; Hild, Eft, Sehissel, D.2; Gillet; 
R.H/ 1. T,~e Chikk'eT~k Hospital, Denver, CO; 2. Unive1"si U of Col- 
ornclo HeMth Scie~ce.r Celzter, DeJmer, CO. 
Nine very young children, ages 2-16 months, with pre-B ALL 
containing rearrangements of he MLL gene at 1 lq23 underwent 
myeloablat ive al logeneic HSCT in CR1 from either HLA 
matched siblings (MS: n=2) or unrelated cord blood donors (UCB: 
n=7). MLL  abnormalit ies included t(4:1i) in 3; t(10:1I) in 1; 
t(11:19) in 4 and 11q23 to an unknown partner in 1. All were 
CD10 negative and 6 of 9 had WBC>50, 000. All patients 
achieved CR1 following >4 drug induction, aggressive multi-agent 
consolidation (including B43-PAP monoclonal antibody in 3), and 
then proceeded to transplant 3 to 4 months after diagnosis. Mye- 
ioablative conditioning was identical in all patients with fraction- 
ated TBI  (1200 cGy with lung shielding at 900 cGy), Cytarabine 
(83 mg/kg x 6 doses), and Cyclophosphamide (45 mg/kg x 2 
doses). UCB recipients also received ATG and Methylpred-  
nisolone (MPred). GVHD prophyla~s was with Methotrexate and 
Cyclosporine A for the MS or CSA/MPred for the UCB recipi- 
ents. Acute GVHD developed in both MS patients (grade 2 skin) 
and 1 UCB recipient (grade 3 GI). Chronic GVI ID did not occur 
in either MS recipient and only 1 UCB recipient (extensive). 
Leukemia-fi'ee survival is 87.5% with a median follow-up of 749 
days (range 60 to 2025 days). To date, the most frequent oxicity 
has been endocrinoparhies (growth hormone deficiency and sub- 
clinical hypothyroidism). All patients have a Lansky Performance 
Score of 80-100% and impairments of neuro-cognitive function 
have been only mild and transient. These observations demon- 
strate that high-risk 1 lq23+ ALL in young children is curable 
with myeloablative stem ceil transplant. These data prompt the 
questions whether similar results could be achieved without TBI 
and whether there is a GVL effect that could be examined using a 
non-myeloablative approach to potentially reduce toxicity. 
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